Q3 2025 Earnings Call Transcript November 3, 2025 BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Altria Group, Inc. (NYSE: MO) today reports our 2025 third-quarter and nine-months business results, announces the expansion of our existing share repurchase program and narrows our guidance for 2025 ...

IR uses the blood vessel network in the body as almost like a subway map. We can get on and off at different stops to access different parts of the body and treat disease. IR is the intersection of ...

A systematic review published today in Psychedelics by Mr. James Gattuso and colleagues at the Florey Institute of Neuroscience and Mental Health synthesizes clinical and preclinical evidence on ...

Zoliflodacin, an investigational single-dose oral antibiotic for uncomplicated gonorrhea, to be featured in oral presentation with key subset analyses from pivotal global Phase 3 trial WALTHAM, Mass.- ...

PRINCETON, N.J., Oct. 16, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that results from the NEW DAY clinical trial of ILUVIEN ® ...

Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients ...

In August, Vor Bio announced topline results from the RemeGen-sponsored study, reporting that telitacicept achieved the primary endpoint of reducing proteinuria demonstrating a 55% reduction in ...

BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as ...

The Committee for Medicinal Products for Human Use, or CHMP, provides recommendations to EMA on human medicines, which the ...

ZURICH--(BUSINESS WIRE)--Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® ...